Sandy Chan
Family · Brooklyn, NYNPI 1205366267
Payments from drug & device makers
Across 164 payments — averaging $23.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exact Sciences$543
- GSK$392
- AbbVie$381
- Gilead$315
- AstraZeneca$286
- Lilly USA, LLC$260
- plus $2K from 28 others
What the payments were for
- Food & beverage$3,850100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exact Sciences | 19 | $543 |
| GSK | 22 | $392 |
| AbbVie | 14 | $381 |
| Gilead | 10 | $315 |
| AstraZeneca | 14 | $286 |
| Lilly USA, LLC | 12 | $260 |
| Amarin Pharma, Inc. | 11 | $224 |
| Esperion Therapeutics, Inc. | 2 | $168 |
| Amgen(2 entities) | 8 | $163 |
| Boehringer Ingelheim | 7 | $159 |
| Mallinckrodt Hospital Products Inc. | 1 | $127 |
| Merck | 5 | $101 |
| Otsuka America Pharmaceutical, Inc. | 4 | $65 |
| Pfizer | 4 | $64 |
| Philips North America LLC | 3 | $62 |
| Lundbeck LLC | 2 | $54 |
| Johnson & Johnson(3 entities) | 3 | $52 |
| IBSA Pharma Inc. | 3 | $50 |
| Eisai Inc. | 2 | $45 |
| Intra-sana Laboratories | 2 | $40 |
| Hikma Pharmaceuticals USA | 2 | $32 |
| Boston Scientific | 1 | $29 |
| Smith+Nephew | 1 | $28 |
| Novo Nordisk | 2 | $27 |
| Shield Therapeutics Inc | 1 | $22 |
| Agios Pharmaceuticals, Inc. | 1 | $22 |
| Madrigal Pharmaceuticals | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| Astellas Pharma US Inc | 1 | $19 |
| Radius Health, Inc. | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,865 in reported general payments places this provider in the 90th percentile of 8,883 family providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanumetSitagliptin Phos/Metformin Hcl | 214 | $194,547 |
| VascepaIcosapent Ethyl | 340 | $188,321 |
| FarxigaDapagliflozin Propanediol | 165 | $171,021 |
| JardianceEmpagliflozin | 155 | $161,260 |
| JanuviaSitagliptin Phosphate | 116 | $109,344 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 141 | $98,482 |
| EliquisApixaban | 73 | $89,839 |
| ProliaDenosumab | 40 | $67,455 |
| VemlidyTenofovir Alafenamide | 42 | $63,226 |
| Diclofenac Sodium | 249 | $61,819 |
| RybelsusSemaglutide | 28 | $61,576 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 85 | $56,566 |
| TradjentaLinagliptin | 56 | $49,319 |
| LinzessLinaclotide | 74 | $40,692 |
| XareltoRivaroxaban | 38 | $40,453 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanumet, Januvia, Janumet Xr | $101 | $315,378342 claims |
| Boehringer IngelheimJardiance, Tradjenta, Jentadueto, Combivent Respimat | $159 | $262,269263 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $286 | $227,587250 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Shingrix, Breo Ellipta | $392 | $130,340239 claims |
| Novo NordiskRybelsus, Ozempic | $27 | $99,66850 claims |
| PfizerEliquis | $64 | $89,83973 claims |
| AbbVieLinzess, Creon, Synthroid | $381 | $68,266194 claims |
| AmgenProlia | $163 | $67,45540 claims |
| GileadVemlidy | $315 | $63,22642 claims |
| Johnson & JohnsonXarelto | $52 | $40,45338 claims |
| Lilly USA, LLCTrulicity | $260 | $35,73021 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $14 | $18,90818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,883 family providers in New York.
Other family in Brooklyn
- Seida VelijaBrooklyn$62K
- Ofiong OkonBrooklyn$44K
- Irina FainbergBrooklyn$23K
- Susan WeissBrooklyn$22K
- Razan AlawadhiBrooklyn$21K
- Christina LaoBrooklyn$20K
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.